|
US7037922B1
(en)
*
|
2000-03-10 |
2006-05-02 |
Neurogen Corporation |
Aryl fused 2,4-disubstituted pyridines: NK3 receptor ligands
|
|
AU4038600A
(en)
|
1999-03-29 |
2000-10-16 |
Neurogen Corporation |
4-substituted quinoline derivatives as nk-3 and/or gaba(a) receptor ligands
|
|
CA2375920A1
(en)
|
1999-06-14 |
2000-12-21 |
Eli Lilly And Company |
Compounds
|
|
US6794393B1
(en)
|
1999-10-19 |
2004-09-21 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
NZ518001A
(en)
|
1999-10-19 |
2004-05-28 |
Merck & Co Inc |
Tyrosine kinase inhibitors
|
|
US6420382B2
(en)
|
2000-02-25 |
2002-07-16 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
US6313138B1
(en)
|
2000-02-25 |
2001-11-06 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
US6521618B2
(en)
|
2000-03-28 |
2003-02-18 |
Wyeth |
3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
|
|
CA2424689A1
(en)
|
2000-10-17 |
2002-04-25 |
Merck & Co., Inc. |
Orally active salts with tyrosine kinase activity
|
|
GB0028964D0
(en)
*
|
2000-11-28 |
2001-01-10 |
Smithkline Beecham Spa |
Novel compounds
|
|
WO2003037252A2
(en)
|
2001-10-30 |
2003-05-08 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
WO2004002484A1
(ja)
*
|
2002-06-26 |
2004-01-08 |
Kyowa Hakko Kogyo Co., Ltd. |
ホスホジエステラーゼ阻害剤
|
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
|
SI2246360T1
(sl)
|
2003-01-28 |
2012-10-30 |
Ironwood Pharmaceuticals Inc |
Sestavki za zdravljenje gastrointestinalnih motenj
|
|
RU2229475C1
(ru)
*
|
2003-03-06 |
2004-05-27 |
ООО "Исследовательский институт химического разнообразия |
6-сульфамоилхинолин-4-карбоновые кислоты, их производные и комбинаторная библиотека
|
|
TW201018662A
(en)
|
2005-12-12 |
2010-05-16 |
Astrazeneca Ab |
Alkylsulphonamide quinolines
|
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
|
ES2559319T3
(es)
|
2007-06-04 |
2016-02-11 |
Synergy Pharmaceuticals Inc. |
Agonistas de guanilato cliclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
|
|
WO2008154207A1
(en)
*
|
2007-06-08 |
2008-12-18 |
The Burnham Institute For Medical Research |
Methods and compounds for regulating apoptosis
|
|
CA2726917C
(en)
|
2008-06-04 |
2018-06-26 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
|
WO2010009319A2
(en)
|
2008-07-16 |
2010-01-21 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
|
|
WO2018129556A1
(en)
|
2017-01-09 |
2018-07-12 |
Ardelyx, Inc. |
Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
|
|
JP5502106B2
(ja)
|
2008-12-31 |
2014-05-28 |
アーデリクス，インコーポレーテッド |
体液貯留または塩分過負荷と関連する障害および消化管障害の治療におけるｎｈｅ媒介性アンチポートを阻害するための組成物および方法
|
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
|
US10376481B2
(en)
|
2012-08-21 |
2019-08-13 |
Ardelyx, Inc. |
Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
|
|
WO2014029983A1
(en)
|
2012-08-21 |
2014-02-27 |
Ardelyx, Inc. |
Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
|
|
CA2905438A1
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase and their uses
|
|
AU2014235209B2
(en)
|
2013-03-15 |
2018-06-14 |
Bausch Health Ireland Limited |
Guanylate cyclase receptor agonists combined with other drugs
|
|
EP2983667B1
(en)
|
2013-04-12 |
2019-03-20 |
Ardelyx, Inc. |
Nhe3-binding compounds and methods for inhibiting phosphate transport
|
|
US9475773B2
(en)
|
2013-04-19 |
2016-10-25 |
Astrazeneca Ab |
NK3 receptor antagonist compound (NK3RA) for use in a method for the treatment of polycystic ovary syndrome (PCOS)
|
|
WO2014197720A2
(en)
|
2013-06-05 |
2014-12-11 |
Synergy Pharmaceuticals, Inc. |
Ultra-pure agonists of guanylate cyclase c, method of making and using same
|
|
JP6560335B2
(ja)
*
|
2014-07-08 |
2019-08-14 |
ダウ アグロサイエンシィズ エルエルシー |
３−ヒドロキシピコリン酸の製造方法
|
|
WO2017072629A1
(en)
|
2015-10-29 |
2017-05-04 |
Cadila Healthcare Limited |
Pharmaceutical combination of nk3 receptor antagonist and biguanides
|
|
EP3565811A1
(en)
|
2017-01-09 |
2019-11-13 |
Ardelyx, Inc. |
Inhibitors of nhe-mediated antiport
|
|
KR20240090875A
(ko)
|
2017-01-09 |
2024-06-21 |
알데릭스, 인코포레이티드 |
위장관 장애를 치료하는 데 유용한 화합물
|
|
US20210401821A1
(en)
*
|
2018-11-15 |
2021-12-30 |
Kyushu University, National University Corporation |
Prophylactic or therapeutic agent and medicinal composition for il-31-mediated disease
|